⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplemental Table 1 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts

Zijie Feng Xuyao Zhang Zhicheng Peng Azin Aghamajidi Yuan Wu Xianxin Hua

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: Nanobody-directed CAR T cells demonstrate efficacy in eliminating gastrointestinal cancer xenografts.
KEY EVIDENCE: Clinical trials show significant tumor reduction in patients with CEA-positive solid tumors.
APPROACH: The study conducted a review of various clinical trials involving CEA-targeted CAR T-cell therapies.
SIGNIFICANCE: These findings provide new insights into targeted cancer therapies, enhancing treatment strategies for solid tumors.

Implication

Clinical trials reveal improved outcomes for gastrointestinal cancer using CEA-targeted CAR T cells, suggesting effective therapy options.

Abstract

Supplemental Table 1: Overview of Clinical Trials Investigating CEA-Targeted CAR T-cell Therapies in CEA-Positive Gastrointestinal and Solid Tumors

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Feng et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0266 https://doi.org/10.1158/2326-6066.29760151

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Data from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts2025
2Supplemental Figure 1 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts2025
3Supplemental Figure 2 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts2025
4Emerging landscape of CAR T-cell therapy in gastrointestinal malignancies: A systematic review of clinical trials.Systematic Review · 2026
5Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion.2024 · 27 citations

More related papers

Supplementary Figure 6 from Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas2025
Effectiveness of CAR-T cells engineered with TGF-βr/IL-9R domain-swapped chimeric receptor and membrane-bound IL-2 for treatment of CEA+ solid tumors.2026
Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells2023